Bayer: Nexavar Lung Cancer Phase III Study Misses Primary Endpoint
FRANKFURT – German chemical and pharmaceutical group Bayer AG (BAYN.XE) and Onyx Pharmaceuticals, Inc. (ONXX) Tuesday said a phase III trial of Nexavar treatment for lung cancer patients failed to meet its primary endpoint of improving overall survival.
"While we are disappointed that the primary endpoint was not met, we believe the study results will advance the scientific knowledge in lung cancer," said Bayer HealthCare's vice president of clinical development oncology, Dimitris Voliotis.
Nexavar is approved in more than 100 countries to treat liver and kidney cancer, generating sales of EUR725 million in 2011 and making it Bayer's fourth biggest drug by sales.
The Nexavar study was conducted on patients with non-small cell lung cancer which progressed after two or three previous treatments. The study compared Nexavar plus best supportive care to a placebo with the same care.